Cystic Fibrosis (CF) is an inherited genetic condition. In other words, this is an inborn disease. This is common in Australia and large parts of the rest of the world. What makes this common in Australia is that every 4 days a baby is born with CF. Moreover, around 1 in every 25 people in Australia are carriers of a CF gene. However what is intriguing is that most of the time, CF carriers don't even know that they have a CF gene.

As there are so many different types of cystic fibrosis, all with a variety of symptoms, there's no typical treatment plan. Recently, the doctors said that a healing treatment that corrects the underlying cause of cystic fibrosis could transform medication.

In a 100 percent population with cystic fibrosis cases, only half of it will make it into their 4os. Yet Clara, a fifteen year old girl who has been using the drug Orkambi for the three past years said that it was life changing. Irregularity in their DNA means it produce thick and sticky mucus substance that blocks which eventually relentlessly damages their lungs.

At the North American Cystic Fibrosis Conference, the data presented exhibits that drugs combination enables production of runnier mucus which slows the predestined decline in lung function. Mistakes in people's DNA or genetic code can lead to defective microscopic machinery in the lungs.

When people get the balance of salt and water wrongly, instead of producing a normal protective layer of mucus, it becomes destructive affirmed the SocialFeed Info. Taking antibiotics can just avoid the drugs to settle in and likely loosen the mucus, however with regards to the basic problem of the patients, it has nothing to deal with it.

The drugs such as lumacaftor and ivacaftor as early studies suggested could change the microscopic machinery so they made runnier mucus. The studies were monitored for 24 weeks with the patients who had that ailment. However, the doctors have a data of it now monitoring them for nearly two years according to Medical Webtimes News.

The doctors did not give any assurance of curing for drug combination is clearly not a cure. But the untreated patients would expect their lung function to decline by 2.3% a year, but this fell to 1.3% in those given the therapy, the researchers said. Moreover, they will seek less of hospital treatment.

From the Case Western Reserve University School of Medicine, Dr Michael Konstan who spearheaded the trial expressed that these data suggest that the lumacaftor/ivacaftor drugs are beneficial for it sustained and indicate that the medicine could modify the progression of cystic fibrosis lung disease by treating its underlying cause.

Furthermore, from the Royal Brompton Hospital in London, Dr. Stuart Elborn, told that this is an incremental advance rather than a breakthrough, but it is very reassuring that the effect does not wear off where some of the patients were treated.

"I'm really excited by the therapy and also the pipeline of other powerful drugs that could get us closer to a cure." said Elborn.

 After it was rejected by funding bodies in England and Scotland, the therapy is not available in NHS. The medication costs more than £100,000 a year for each patient. It was observed that there are also many types of error in the DNA that can culminate in cystic fibrosis.

The remaining patients are still required for the new treatments. In the UK one in every 2,500 babies has cystic fibrosis.